CXCR4 and cancer: The first to enter clinical trials was ALX-0651, a biparatopic anti-CXCR4 nanobody for use in cancer therapy that was selected from a library generated from peripheral blood mononuclear cells of llamas that were immunised with HEK293T cells expressing CXCR4.